1.0Public Citizenhttps://www.citizen.orgDiane Krauthamerhttps://www.citizen.org/author/dkrauthamer/Follow-Up Letter to FDA Regarding Canakinumab (Ilaris) - Public Citizenrich600338<blockquote class="wp-embedded-content" data-secret="pTxIvgyHvU"><a href="https://www.citizen.org/article/follow-up-letter-to-fda-regarding-canakinumab-ilaris/">Follow-Up Letter to FDA Regarding Canakinumab (Ilaris)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/follow-up-letter-to-fda-regarding-canakinumab-ilaris/embed/#?secret=pTxIvgyHvU" width="600" height="338" title="“Follow-Up Letter to FDA Regarding Canakinumab (Ilaris)” — Public Citizen" data-secret="pTxIvgyHvU" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
These comments from the Public Citizen Health Research Group (HRG) are being submitted to follow up on our testimony presented at the June 21, 2011 meeting of the Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) regarding the supplemental Biologics License Application (sBLA) #125319 for the drug canakinumab (Ilaris).https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg1200628